PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 35/76, A61P 35/00 — A2

(11) International Publication Number: **WO 00/50051**

(43) International Publication Date: 31 August 2000 (31.08.00)

(21) International Application Number: PCT/CA00/00178

(22) International Filing Date: 18 February 2000 (18.02.00)

(30) Priority Data:
09/256,824 24 February 1999 (24.02.99) US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application
US 09/256,824 (CON)
Filed on 24 February 1999 (24.02.99)

(71) Applicant *(for all designated States except US)*: ONCOLYTICS BIOTECH, INC. [CA/CA]; 301, 1211 Kensington Road N.W., Calgary, Alberta T2N 3P6 (CA).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: LEE, Patrick, W., K. [CA/CA]; 22 Varmoor Place, N.W., Calgary, Alberta T3A 0A1 (CA). STRONG, James [CA/CA]; 5071 Nesbitt Road N.W., Calgary, Alberta T2K 2N6 (CA). COFFEY, Matthew, C. [CA/CA]; 408, 1111 13th Avenue S.W., Calgary, Alberta T2R 0L7 (CA).

(74) Agent: DONAHUE ERNST & YOUNG; Ernst & Young Tower, 222 Bay Street, Suite 1800, P.O. Box 197, T.D. Centre, Toronto, Ontario M5K 1H6 (CA).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: REOVIRUS FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS

(57) Abstract

Methods for treating proliferative disorders, by administering reovirus to a Ras–mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras–mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non–human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.